INTELLIA THERAPEUTICS COMPLETES ENROLLMENT IN PHASE 3 MAGNITUDE-2 TRIAL OF NEXIGURAN ZICLUMERAN (NEX-Z) FOR PATIENTS WITH HEREDITARY TRANSTHYRETIN AMYLOIDOSIS WITH POLYNEUROPATHY (ATTRV-PN)

Reuters · 20h ago

Please log in to view news